ORION: A Global Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy (A35-009)
Objective: Here we describe ORION, a phase 3 trial assessing efficacy and safety of AMX0035 in progressive supranuclear palsy (PSP). Background: PSP is a rare,…Clinical and neuroimaging factors associated with survival in Progressive Supranuclear Palsy
Objective: To assess clinical and neuroimaging factors associated with survival in a cohort of patients with a final clinical diagnosis of Progressive Supranuclear Palsy (PSP)…Metabolic Covariance Networks in Progressive Supranuclear Palsy Revealed by Spatial independent component analysis
Objective: The study aims to apply S-ICA to 18F-fluorodeoxyglucose (FDG) data in progressive supranuclear palsy (PSP) patients, identifing PSP-specific independent metabolic covariate networks. We also…Noradrenaline treatment of apathy and impulsivity in participants with Progressive Supranuclear Palsy syndromes (NORAPS). A Phase II clinical trial – ISRCTN99462035.
Objective: The NORAPS Phase II clinical trial seeks to demonstrate safety, tolerability and efficacy of atomoxetine in Progressive Supranuclear Palsy (PSP). Background: PSP is a…Paraneoplastic neurological syndrome mimicking a progressive supranuclear palsy: a case series
Objective: we describe 2 patients with paraneoplastic parkinsonism mimicking a PSP. Background: Paraneoplastic neurological syndromes (PNS) are broad-spectrum disorders that can affect any part of…Frequency of Falls as a Presenti̇ng Symptom and Its Effect i̇n Prognosi̇s i̇n Progressi̇ve Supranuclear Palsy
Objective: We aimed to evaluate frequency of falls as a presenting symptom and its effect on prognosis in PSP patients. Background: Progressive supranuclear palsy is…Neuronal Exosome based markers in Parkinson’s Disease and Progressive Supranuclear Palsy
Objective: This study aimed to explore cellular inflammatory and autophagic mediators in neuronal exosomes of PD and PSP. Background: Parkinson’s disease (PD) is a common…Subjective cognitive complaints in patients with progressive supranuclear palsy and corticobasal syndrome
Objective: In the present study, we evaluate a prevalence of subjective cognitive complaints (SCC)in patients with progressive supranuclear palsy (PSP) as well as clinical features…Phenotypic characterization of 104 patients with Progressive Supranuclear Palsy: A Tertiary care experience from South India
Objective: To prospectively evaluate and subtype the patients of Progressive supranuclear palsy being referred to a tertiary care movement disorders facility in South India. Background:…Differential effect of MAPT haplotype on survival in CBD and PSP-SCB phenotype
Objective: Evaluate the association of MAPT haplotype with the risk of PSP-CBS and CBD severity of tau pathology by studying the survival rate of both…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 42
- Next Page »